Cognition and the five-factor model of the Positive and Negative Syndrome Scale in schizophrenia

Schizophrenia Research

Volumn 143, Issue 1, 2013, Pages 77-83

  Rodriguez Jimenez, Roberto ^a,b   Bagney, Alexandra ^a,b   Mezquita, Laura ^c   Martinez Gras, Isabel ^a,b   Sanchez Morla, Eva Maria ^d   Mesa, Natalia ^a   Ibañez, Manuel Ignacio ^c   Diez Martin, Justo ^a   Jimenez Arriero, Miguel Angel ^a,b   Lobo, Antonio ^b,e   Santos, Jose Luis ^f   Palomo, Tomas ^a,b  

^a Instituto de Investigación Hospital 12 de Octubre ^*  (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSITAT JAUME I   (Spain)

^d HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^f HOSPITAL VIRGEN DE LA LUZ   (Spain)

Author keywords

CFA; Cognition; Cognitive factor; PANSS; Schizophrenia; WCST

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONSENSUS; CRONBACH ALPHA COEFFICIENT; CROSS-SECTIONAL STUDY; ETHNIC GROUP; FACTORIAL ANALYSIS; FEMALE; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOMETRY; RELIABILITY; SCHIZOPHRENIA; SPANISH; WISCONSIN CARD SORTING TEST;

ADOLESCENT; ADULT; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PRINCIPAL COMPONENT ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84871938885     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.10.020     Document Type: Article

References (95)

1. Addington J., Brooks B.L., Addington D. Cognitive functioning in first episode psychosis: initial presentation. Schizophr. Res. 2003, 62:59-64.
2. Aish A.M., Joreskog K.G. A panel model for political efficacy and responsiveness: an application of LISREL 7 with weighted least squares. Qual. Quant. 1990, 19:716-723.
3. Albus M., Hubmann W., Ehrenberg Ch., Forcht U., Mohr F., Sobizack N., Wahlheim C., Hecht S. Neuropsychological impairment in first-episode and chronic schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci. 1996, 246:249-255.
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
5. Asarnow R.F., MacCrimmon D.J. Residual performance deficit in clinically remitted schizophrenics: a marker of schizophrenia?. J. Abnorm. Psychol. 1978, 87:597-608.
6. Bell M.D., Lysaker P.H., Beam-Goulet J.L., Milstein R.M., Lindenmayer J.P. Five-component model of schizophrenia: assessing the factorial invariance of the Positive and Negative Syndrome Scale. Psychiatry Res. 1994, 52:295-303.
7. Bell M.D., Lysaker P.H., Milstein R.M., Beam-Goulet J.L. Concurrent validity of the cognitive component of schizophrenia: relationship of PANSS scores to neuropsychological assessments. Psychiatry Res. 1994, 54:51-58.
8. Bentler P.M. EQS6 Structural Equations Program Manual 1995, Multivariate Software Inc., Encino.
9. Bentler P.M., Wu E.J.C. EQS for Windows User's Guide 1995, Multivariate Software Inc., Encino.
10. Bentler P.M., Berkane M., Kano Y. Covariance structure analysis under a simple kurtosis model. Computing Science and Statistics 1991, 463-465. Interface Foundation of North America, Fairfax Station. E.M. Keramidas (Ed.).
11. Bleuler E. Dementia Praecox or the Group of Schizophrenias 1950, International Universities Press, New York.
12. Bowie C.R., Harvey P.D. Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr. Clin. North Am. 2005, 28(613-633):626.
13. Bowie C.R., Reichenberg A., Patterson T.L., Heaton R.K., Harvey P.D. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J. Psychiatry 2006, 163:418-425.
14. Bowie C.R., Leung W.W., Reichenberg A., McClure M.M., Patterson T.L., Heaton R.K., Harvey P.D. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol. Psychiatry 2008, 63:505-511.
15. Bozikas V.P., Kosmidis M.H., Kioperlidou K., Karavatos A. Relationship between psychopathology and cognitive functioning in schizophrenia. Compr. Psychiatry 2004, 45:392-400.
16. Brown T.A. Confirmatory Factor Analysis for Applied Research 2006, Guilford Press, New York.
17. Bryson G., Bell M., Greig T., Kaplan E. Internal consistency, temporal stability and neuropsychological correlates of three cognitive components of the Positive and Negative Syndrome Scale (PANSS). Schizophr. Res. 1999, 38:27-35.
18. Byrne B.M. Structural Equation Modeling With EQS: Basic Concepts, Applications, and Programming 2006, Erlbaum, Mahwah. Second ed.
19. Cameron A.M., Oram J., Geffen G.M., Kavanagh D.J., McGrath J.J., Geffen L.B. Working memory correlates of three symptom clusters in schizophrenia. Psychiatry Res. 2002, 110:49-61.
20. Citrome L., Meng X., Hochfeld M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr. Res. 2011, 131:75-81.
21. Cornblatt B.A., Lenzenweger M.F., Dworkin R.H., Erlenmeyer-Kimling L. Childhood attentional dysfunctions predict social deficits in unaffected adults at risk for schizophrenia. Br. J. Psychiatry Suppl. 1992, 18:59-64.
22. Crow T.J. Molecular pathology of schizophrenia: more than one disease process?. Br. Med. J. 1980, 280:66-68.
23. Cuesta M.J., Peralta V., Caro F., De Leon J. Schizophrenic syndrome and Wisconsin Card Sorting Test card dimensions. Psychiatry Res. 1995, 58:45-51.
24. Daban C., Amado I., Bayle F., Gut A., Willard D., Bourdel M.C., Loo H., Olie J.P., Millet B., Krebs M.O., Poirier M.F. Correlation between clinical syndromes and neuropsychological tasks in unmedicated patients with recent onset schizophrenia. Psychiatry Res. 2002, 113:83-92.
25. Dibben C.R., Rice C., Laws K., McKenna P.J. Is executive impairment associated with schizophrenic syndromes? A meta-analysis. Psychol. Med. 2009, 39:381-392.
26. Dollfus S., Petit M. Principal-component analyses of PANSS and SANS-SAPS in schizophrenia: their stability in an acute phase. Eur. Psychiatry 1995, 10:97-106.
27. Drake R.J., Dunn G., Tarrier N., Haddock G., Haley C., Lewis S. The evolution of symptoms in the early course of non-affective psychosis. Schizophr. Res. 2003, 63:171-179.
28. Ehmann T.S., Khanbhai I., Macewan G.W., Smith G.N., Honer W.G., Flynn S., Altman S. Neuropsychological correlates of the PANSS cognitive factor. Psychopathology 2004, 37:253-258.
29. Eisenberg D.P., Berman K.F. Executive function, neural circuitry, and genetic mechanisms in schizophrenia. Neuropsychopharmacology 2010, 35:258-277.
30. El Yazaji M., Battas O., Agoub M., Moussaoui D., Gutknecht C., Dalery J., D'Amato T., Saoud M. Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia. Schizophr. Res. 2002, 56:121-127.
31. Emsley R., Rabinowitz J., Torreman M., RIS-INT-35 Early Psychosis Global Working Group The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr. Res. 2003, 61:47-57.
32. Erlenmeyer-Kimling L., Cornblatt B. Attentional measures in a study of children at high-risk for schizophrenia. J. Psychiatr. Res. 1978, 14:93-98.
33. Field A. Discovering Statistics Using SPSS 2009, Sage Publications, Thousand Oaks, CA. 3rd ed.
34. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0) 1995, Biometrics Research Department, New York State Psychiatric Institute, New York.
35. Fredrikson D., Steiger J., MacEwan G., Altman S., Kopala L., Flyn S., Liddle P., Honer W. PANSS symptom factors in schizophrenia. Schizophr. Res. 1997, 24:15.
36. Fresán A., De La Fuente-Sandoval C., Loyzaga C., García-Anaya M., Meyenberg N., Nicolini H., Apiquian R. A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenia patients. Schizophr. Res. 2005, 72:123-129.
37. Fuller R., Nopoulos P., Arndt S., O'Leary D., Ho B.C., Andreasen N.C. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardised scholastic test performance. Am. J. Psychiatry 2002, 159:1183-1189.
38. Goldstein G., Shermansky W.J. Influences on cognitive heterogeneity in schizophrenia. Schizophr. Res. 1995, 18:59-69.
39. Good K.P., Rabinowitz J., Whitehorn D., Harvey P.D., DeSmedt G., Kopala L.C. The relationship of neuropsychological test performance with the PANSS in antipsychotic naive, first-episode psychosis patients. Schizophr. Res. 2004, 68:11-19.
40. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153:321-330.
41. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26:119-136.
42. Harvey P.D., Howanitz E., Parrella M., White L., Davidson M., Mohs R.C., Hoblyn J., Davis K.L. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am. J. Psychiatry 1998, 155:1080-1086.
43. Harvey P.D., Serper M.R., White L., Parrella M.J., McGurk S.R., Moriarty P.J., Bowie C., Vadhan N., Friedman J., Davis K.L. The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia. Compr. Psychiatry 2001, 42:306-313.
44. Heinrichs R.W., Awad A.G. Neurocognitive subtypes of chronic schizophrenia. Schizophr. Res. 1993, 9:49-58.
45. Higashima M., Urata K., Kawasaki Y., Maeda Y., Sakai N., Mizukoshi C., Nagasawa T., Kamiya T., Yamaguchi N., Koshino Y. P300 and the thought disorder factor extracted by factor-analytic procedures in schizophrenia. Biol. Psychiatry 1998, 44:115-120.
46. Hofer A., Niedermayer B., Kemmler G., Rettenbacher M.A., Trebo E., Widschwendter C.G., Fleischhacker W.W. Cognitive impairment in schizophrenia: clinical ratings are not a suitable alternative to neuropsychological testing. Schizophr. Res. 2007, 92:126-131.
47. Hutton S.B., Puri B.K., Duncan L.J., Robbins T.W., Barnes T.R., Joyce E.M. Executive function in first-episode schizophrenia. Psychol. Med. 1998, 28:463-473.
48. Joyce E.M., Hutton S.B., Mutsatsa S.H., Barnes T.R. Cognitive heterogeneity in first episode schizophrenia. Br. J. Psychiatry 2005, 187:516-522.
49. Kawasaki Y., Maeda Y., Sakai N., Higashima M., Urata K., Yamaguchi N., Kurachi M. Evaluation and interpretation of symptom structures in patients with schizophrenia. Acta Psychiatr. Scand. 1994, 89:399-404.
50. Kay S.R., Sevy S. Pyramidical model of schizophrenia. Schizophr. Bull. 1990, 16:537-545.
51. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
52. Keefe R.S., Fenton W.S. How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophr. Bull. 2007, 33:912-920.
53. Kline R.B. Principles and Practice of Structural Equation Modeling 2010, Guilford Press, Guilford, New York.
54. Koren D., Seidman L.J., Harrison R.H., Lyons M.J., Kremen W.S., Caplan B., Goldstein J.M., Faraone S.V., Tsuang M.T. Factor structure of the Wisconsin Card Sorting Test: dimensions of deficit in schizophrenia. Neuropsychology 1998, 12:289-302.
55. Kraepelin E. Dementia Praecox and Paraphrenia 1919, E. & S Livingstone, Edinburgh.
56. Kremen W.S., Buka S.L., Seidman L.J., Goldstein J.M., Koren D., Tsuang M.T. IQ decline during childhood and adult psychotic symptoms in a community sample: a 19-year longitudinal study. Am. J. Psychiatry 1998, 155:672-677.
57. Kuha A., Tuulio-Henriksson A., Eerola M., Perälä J., Suvisaari J., Partonen T., Lönnqvist J. Impaired executive performance in healthy siblings of schizophrenia patients in a population-based study. Schizophr. Res. 2007, 92:142-150.
58. Lançon C., Auquier P., Nayt G., Reine G. Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophr. Res. 2000, 42:231-239.
59. Lee K.-H., Harris A.W., Loughland C.M., Williams L.M. The five symptom dimensions and depression in schizophrenia. Psychopathology 2003, 36:226-233.
60. Lehoux C., Gobeil M.H., Lefebvre A.A., Maziade M., Roy M.A. The five-factor structure of the PANSS: a critical review of its consistency across studies. Clin. Schizophr. Relat. Psychoses 2009, 3:103-110.
61. Lépine J.P. Dimensions positives et négatives dans les schizophrénies. Cah. prism 1991, 1:23-29.
62. Levine S.Z., Rabinowitz J. Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale. J. Clin. Psychopharmacol. 2007, 27:431-436.
63. Lindenmayer J.P., Bernstein-Hyman R., Grochowski S. Five-factor model of schizophrenia. Initial validation. J. Nerv. Ment. Dis. 1994, 182:631-638.
64. Lindenmayer J.P., Grochowski S., Hyman R.B. Five factor model of schizophrenia: replication across samples. Schizophr. Res. 1995, 14:229-234.
65. Lindstrom E., Von Knorring L. Principal component analysis of the Swedish version of the Positive and Negative Syndrome Scale for schizophrenia. Nord. J. Psychiatry 1993, 47:257-263.
66. Loewenthal K.M. An Introduction to Psychological Tests and Scales 1996, UCL Press Limited, London.
67. Lykouras L., Oulis P., Psarros K., Daskalopoulou E., Botsis A., Christodoulou V.N., Stefanis C. Five-factor model of schizophrenic psychopathology: how valid is it?. Eur. Arch. Psychiatry Clin. Neurosci. 2000, 250:93-100.
68. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 1997, 58:538-546.
69. Mardia K.V. Measures of multivariate skewness and kurtosis with applications. Biometrika 1970, 57:519-530.
70. Martínez-Arán A., Penadés R., Vieta E., Colom F., Reinares M., Benabarre A., Salamero M., Gastó C. Executive function in patients with remitted bipolar disorder and schizophrenia and its relationship with functional outcome. Psychother. Psychosom. 2002, 71:39-46.
71. Mass R., Schoemig T., Hitschfeld K., Wall E., Haasen C. Psychopathological syndromes of schizophrenia: evaluation of the dimensional structure of the Positive and Negative Syndrome Scale. Schizophr. Bull. 2000, 26:167-177.
72. Mohamed S., Paulsen J.S., O'Leary D., Arndt S., Andreasen N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch. Gen. Psychiatry 1999, 56:749-754.
73. Nieuwenstein M.R., Aleman A., De Haan D.H. Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. J. Psychiatry Res. 2001, 35:119-125.
74. Nuechterlein K.H. Signal detection in vigilance tasks and behavioral attributes among offspring of schizophrenic mothers and among hyperactive children. J. Abnorm. Psychol. 1983, 92:4-28.
75. Nuechterlein K.H., Dawson M.E., Gitlin M., Ventura J., Goldstein M.J., Snyder K.S., Yee C.M., Mintz J. Developmental processes in schizophrenic disorders: longitudinal studies of vulnerability and stress. Schizophr. Bull. 1992, 18:387-425.
76. Pantelis C., Barnes T.R., Nelson H.E., Tanner S., Weatherley L., Owen A.M., Robbins T.W. Frontal-striatal cognitive deficits in patients with chronic schizophrenia. Brain 1997, 120:1823-1843.
77. Paulhus D.L., Robins R.W., Trzesniewski K.H., Tracy J.L. Two replicable suppressor situations in personality research. Multivar. Behav. Res. 2004, 39:303-328.
78. Peña J., Ojeda N., Segarra R., Eguiluz J.I., García J., Gutiérrez M. Executive functioning correctly classified diagnoses in patients with first-episode psychosis: evidence from a 2-year longitudinal study. Schizophr. Res. 2011, 126:77-80.
79. Penadés R., Catalán R., Puig O., Masana G., Pujol N., Navarro V., Guarch J., Gastó C. Executive function needs to be targeted to improve social functioning with Cognitive Remediation Therapy (CRT) in schizophrenia. Psychiatry Res. 2010, 177:41-45.
80. Peralta V., Cuesta M.J. Validation of Positive and Negative Symptom Scale (PANSS) in a sample of Spanish schizophrenic patients. Actas Luso Esp. Neurol. Psiquiatr. Cienc. Afines 1994, 22:171-177.
81. Reed R.A., Harrow M., Herbener E.S., Martin E.M. Executive function in schizophrenia: is it linked to psychosis and poor life functioning?. J. Nerv. Ment. Dis. 2002, 190:725-732.
82. Reichenberg A. The assessment of neuropsychological functioning in schizophrenia. Dialogues Clin. Neurosci. 2010, 12:383-392.
83. Rhinewine J.P., Lencz T., Thaden E.P., Cervellione K.L., Burdick K.E., Henderson I., Bhaskar S., Keehlisen L., Kane J., Kohn N., Fisch G.S., Bilder R.M., Kumra S. Neurocognitive profile in adolescents with early-onset schizophrenia: clinical correlates. Biol. Psychiatry 2005, 58:705-712.
84. Robbins T.W., Arnsten A.F. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu. Rev. Neurosci. 2009, 32:267-287.
85. Rocca P., Montemagni C., Castagna F., Giugiario M., Scalese M., Bogetto F. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:373-379.
86. Saykin A.J., Shtasel D.L., Gur R.E., Kester D.B., Mozley L.H., Stafiniak P., Gur R.C. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry 1994, 51:124-131.
87. Tirupati S.N., Padmavati R., Thara R., McCreadie R.G. Psychopathology in never treated schizophrenia. Compr. Psychiatry 2006, 47:1-6.
88. Torrey E.F. Studies of individuals with schizophrenia never treated with antipsychotic medication: a review. Schizophr. Res. 2002, 58:101-115.
89. Van Den Oord E.J., Rujescu D., Robles J.R., Giegling I., Birrell C., Bukszár J., Murrelle L., Möller H.J., Middleton L., Muglia P. Factor structure and external validity of the PANSS revisited. Schizophr. Res. 2006, 82:213-223.
90. Van Der Gaag M., Hoffman T., Remijsen M., Jihman R., De Haan L., Van Meijel B., Van Harten P.N., Valmaggia L., De Hert M., Cuijpers A., Wiersma D. The five factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr. Res. 2006, 85:280-287.
91. Velligan D.I., Mahurin R.K., Diamond P.L., Hazelton B.C., Eckert S.L., Miller A.L. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr. Res. 1997, 25:21-31.
92. Wallwork R.S., Fortgang R., Hashimoto R., Weinberger D.R., Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr. Res. 2012, 137:246-250.
93. Weickert T., Goldberg T., Gold J., Bigelow L.B., Egan M.F., Weinberger D.R. Cognitive impairment in patients with schizophrenia displaying preserved and compromised intellect. Arch. Gen. Psychiatry 2000, 57:907-913.
94. White L., Harvey P.D., Opler L., Lindenmayer J.P. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology 1997, 30:263-274.
95. Wolthaus J.E., Dingemans P.M., Schene A.H., Linszen D.H., Knegtering H., Holthausen E.A., Cahn W., Hijman R. Component structure of the Positive and Negative Syndrome Scale (PANSS) in patients with recent-onset schizophrenia and spectrum disorders. Psychopharmacology (Berlin, Ger.) 2000, 150:399-403.